News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

Jun 14, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of...

More
Jun 5, 2018

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Jefferies 2018 Healthcare Conference in...

More
Jun 2, 2018
Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced presentation of preliminary data from the ongoing PIVOT Phase 1/2 Study, which is evaluating the combination...

More
May 31, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NKTR-181, a new molecular entity (NME) and the...

More
May 16, 2018
Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, which is...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide